Last year, the Food and Drug Administration approved Osphena (ospemifene) to treat vaginal atrophy
related to menopause.
Management of post-menopausal vaginal atrophy
and atrophic vaginitis.
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy
can also be a serious effect of the menopause, although I think we're ashamed to talk about this.
A snapshot of the global therapeutic scenario for Vaginal Atrophy
18, 2015 /PRNewswire-iReach/ -- The report " Vaginal Atrophy
(Atrophic Vaginitis) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Vaginal Atrophy
(Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
com/prnh/20130307/600769 Vaginal atrophy
is defined as a decrease in estrogen production.
In fact, declining hormone levels can lead to vaginal atrophy
-- around half of women say intercourse becomes so painful (because of thinning, fragile tissue) that they avoid it.
Fernard Labrie and coworkers at Laval University, Quebec, showed that intravaginal DHEA was highly and rapidly effective for the treatment of vaginal atrophy
(Menopause 2009; 16:907-22), significantly improved the patients' libido and sexual function (Menopause 2009; 16:923-31) and did so with no suggestion of an increase in serum sex steroid levels (Menopause 2009; 16:897-906).
The main assessment criteria were sexual dysfunction parameters of libido, arousal, orgasm, and dyspareunia in postmenopausal women who have vaginal atrophy
Very low dosages of transvaginal oestrogens in the forms of creams, tablets and rings are effective for vaginal atrophy
and urinary incontinence.
The survey showed that nearly 39 pct of post-menopausal women experience these symptoms of vaginal atrophy
and 40 percent agree that it interferes with their sex life.